Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998, for Targeted Genetics Corporation (a development stage company). The registrant is engaged in gene and cell therapy research and development. As of May 4, 1998, there were 28,919,381 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $276,187 | $405,973 |
| Net Loss | $(3,780,021) | $(3,475,028) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.17) |
| Cash and Cash Equivalents (End of Period) | $556,399 | $892,618 |
| Securities Available for Sale | $1,286,967 | $4,025,976 |
| Total Current Liabilities | $3,241,285 | $2,658,735 |
| Long-Term Obligations | $1,599,055 | $1,516,762 |
| Net Cash Used in Operating Activities | $(2,795,986) | $(3,182,796) |
Liquidity: Total liquid assets (cash, cash equivalents, and securities available for sale) were approximately $1.8 million as of March 31, 1998, down from $5.0 million at December 31, 1997.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by approximately 32% year-over-year, primarily driven by a drop in investment income from $230,336 to $42,304 due to lower average cash balances.
- Increased Net Loss: Net loss increased by approximately 9% to $3.78 million. This increase was largely attributable to a one-time restructuring charge of approximately $300,000.
- Expense Composition: Research and development (R&D) expenses rose to $3.21 million (from $3.05 million), and General and Administrative (G&A) expenses rose to $777,000 (from $743,000). Excluding non-recurring restructuring costs, both categories showed a modest decrease.
- Balance Sheet: Cash and securities available for sale decreased significantly due to operational funding and principal payments on capital leases.
Guidance, Outlook, and Risks
- Restructuring: In February 1998, the Company announced a reorganization to reduce operating expenses, cutting approximately 24 management and staff positions. The workforce was reduced to 66 employees (51 in R&D).
- Capital Raise: In April 1998 (subsequent to the reporting period), the Company completed a private placement of common stock and warrants, raising net proceeds of approximately $12.7 million.
- Liquidity Outlook: Management estimates that existing resources combined with the April 1998 proceeds will fund operations through the second quarter of 1999. However, the Company expects to incur substantial additional losses and will need to raise further capital.
- Risks: The Company is in the development stage with no anticipated product-related revenues for several years. Success depends on scientific progress, regulatory approvals, and the ability to secure additional financing on favorable terms.
Investor Verification Checklist
- Verify the utilization of the $12.7 million raised in the April 1998 private placement.
- Confirm the progress of the three lead product opportunities: tgAAV-CFTR (cystic fibrosis), tgDCC-E1A (cancer), and cytotoxic T lymphocytes (infectious diseases).
- Monitor the Company's ability to reduce operating expenses as planned following the restructuring.
- Assess the timeline for potential future capital raises given the projected runway through Q2 1999.
- Review the status of collaborative agreements, specifically with Laboratoires Fournier S.C.A.